Literature DB >> 20463757

Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection.

C-S Hong1, W Fellows, A Niranjan, S Alber, S Watkins, J B Cohen, J C Glorioso, P Grandi.   

Abstract

Oncolytic herpes simplex virus (oHSV) vectors have shown promise in the treatment of patients with recurrent brain tumors although few complete responses have accrued. Impediments to effective therapy include limited vector distribution on delivery, a consequence of injected virion particle trapping in the tumor extracellular matrix (ECM). To enhance virus delivery and spread, we investigated the use of the matrix metalloproteinase-9 (MMP-9) as a means to degrade collagen type IV, a major component of the ECM and basement membranes of gliomas that is absent in normal brain tissue. SK-N-AS neuroblastoma cells were transduced for constitutive, elevated expression of MMP-9, which did not enhance tumor cell migration in vitro or tumor progression in a murine xenograft brain tumor model. MMP-9 expression improved the distribution and infection of oHSV vectors in spheroid model in vitro. Furthermore, MMP9 induced a vector infection over larger areas of brain tumors in vivo. These results suggest that vector delivery and distribution in vivo can be improved by compromising the ECM, potentially enhancing oncolytic efficacy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463757      PMCID: PMC3228315          DOI: 10.1038/gt.2010.66

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  18 in total

1.  Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion.

Authors:  S Kondraganti; S Mohanam; S K Chintala; Y Kin; S L Jasti; C Nirmala; S S Lakka; Y Adachi; A P Kyritsis; F Ali-Osman; R Sawaya; G N Fuller; J S Rao
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

2.  Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion.

Authors:  Sajani S Lakka; Mannari Rajan; Christopher Gondi; Niranjan Yanamandra; Nirmala Chandrasekar; Sushma L Jasti; Yoshiaki Adachi; Khawar Siddique; Meena Gujrati; William Olivero; Dzung H Dinh; Gregory Kouraklis; Athanassios P Kyritsis; Jasti S Rao
Journal:  Oncogene       Date:  2002-11-14       Impact factor: 9.867

Review 3.  Invasion of human glioma: role of extracellular matrix proteins.

Authors:  S K Chintala; J K Rao
Journal:  Front Biosci       Date:  1996-11-01

Review 4.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

5.  MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis.

Authors:  L M Coussens; C L Tinkle; D Hanahan; Z Werb
Journal:  Cell       Date:  2000-10-27       Impact factor: 41.582

6.  Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration.

Authors:  A Niranjan; S Moriuchi; L D Lunsford; D Kondziolka; J C Flickinger; W Fellows; S Rajendiran; M Tamura; J B Cohen; J C Glorioso
Journal:  Mol Ther       Date:  2000-08       Impact factor: 11.454

7.  The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1.

Authors:  T Yoshizaki; H Sato; M Furukawa; J S Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

8.  Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

Authors:  Gheeyoung Choe; Jun K Park; Lisa Jouben-Steele; Thomas J Kremen; Linda M Liau; Harry V Vinters; Timothy F Cloughesy; Paul S Mischel
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

Review 9.  Regulation of matrix metalloproteinases: an overview.

Authors:  Sajal Chakraborti; Malay Mandal; Sudip Das; Amritlal Mandal; Tapati Chakraborti
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

10.  LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway.

Authors:  Padmaja Kunapuli; Chitta S Kasyapa; Lesleyann Hawthorn; John K Cowell
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

View more
  28 in total

1.  New Methods in Tissue Engineering: Improved Models for Viral Infection.

Authors:  Vyas Ramanan; Margaret A Scull; Timothy P Sheahan; Charles M Rice; Sangeeta N Bhatia
Journal:  Annu Rev Virol       Date:  2014-11       Impact factor: 10.431

2.  Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.

Authors:  Nina Dmitrieva; Lianbo Yu; Mariano Viapiano; Timothy P Cripe; E Antonio Chiocca; Joseph C Glorioso; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2010-12-21       Impact factor: 12.531

3.  Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography.

Authors:  Alan R Penheiter; David Dingli; Claire E Bender; Stephen J Russell; Stephanie K Carlson
Journal:  J Gene Med       Date:  2012 Sep-Oct       Impact factor: 4.565

4.  Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2012-06-12       Impact factor: 11.454

Review 5.  Oncolytic Virotherapy: A Contest between Apples and Oranges.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2017-04-06       Impact factor: 11.454

Review 6.  Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.

Authors:  Ryuichi Kanai; Samuel D Rabkin
Journal:  CNS Oncol       Date:  2013-03

Review 7.  Digesting a Path Forward: The Utility of Collagenase Tumor Treatment for Improved Drug Delivery.

Authors:  Aaron Dolor; Francis C Szoka
Journal:  Mol Pharm       Date:  2018-05-16       Impact factor: 4.939

8.  Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy.

Authors:  Lulu Hu; Sulan Sun; Tianpeng Wang; Yingchun Li; Ke Jiang; Guibin Lin; Yan Ma; Martin P Barr; Fei Song; Guirong Zhang; Songshu Meng
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

9.  Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.

Authors:  Lucia Mazzacurati; Marco Marzulli; Bonnie Reinhart; Yoshitaka Miyagawa; Hiroaki Uchida; William F Goins; Aofei Li; Balveen Kaur; Michael Caligiuri; Timothy Cripe; Ennio A Chiocca; Nino Chiocca; Nduka Amankulor; Justus B Cohen; Joseph C Glorioso; Paola Grandi
Journal:  Mol Ther       Date:  2014-09-09       Impact factor: 11.454

10.  Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation.

Authors:  B Thaci; I V Ulasov; A U Ahmed; S D Ferguson; Y Han; M S Lesniak
Journal:  Gene Ther       Date:  2012-06-07       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.